DE602004027529D1 - Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln - Google Patents

Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln

Info

Publication number
DE602004027529D1
DE602004027529D1 DE602004027529T DE602004027529T DE602004027529D1 DE 602004027529 D1 DE602004027529 D1 DE 602004027529D1 DE 602004027529 T DE602004027529 T DE 602004027529T DE 602004027529 T DE602004027529 T DE 602004027529T DE 602004027529 D1 DE602004027529 D1 DE 602004027529D1
Authority
DE
Germany
Prior art keywords
antiglykan
mirrors
antibody
measurements
diagnostic procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004027529T
Other languages
English (en)
Inventor
Nir Dotan
Avinoam Dukler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycominds Ltd
Original Assignee
Glycominds Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycominds Ltd filed Critical Glycominds Ltd
Priority claimed from PCT/IB2004/004389 external-priority patent/WO2005054853A2/en
Publication of DE602004027529D1 publication Critical patent/DE602004027529D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/94—Saccharomyces
    • Y10S435/942—Saccharomyces cerevisiae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602004027529T 2003-12-03 2004-12-03 Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln Active DE602004027529D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/728,227 US7592150B2 (en) 2003-12-03 2003-12-03 Method for diagnosing diseases based on levels of anti-glycan antibodies
US10/843,033 US20050142618A1 (en) 2003-12-03 2004-05-11 Method for diagnosing diseases based on levels of anti-glycan antibodies
PCT/IB2004/004389 WO2005054853A2 (en) 2003-12-03 2004-12-03 Method for diagnosing diseases based on levels of anti-glycan antibodies

Publications (1)

Publication Number Publication Date
DE602004027529D1 true DE602004027529D1 (de) 2010-07-15

Family

ID=34633661

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027529T Active DE602004027529D1 (de) 2003-12-03 2004-12-03 Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln

Country Status (5)

Country Link
US (3) US7592150B2 (de)
AT (1) ATE470152T1 (de)
DE (1) DE602004027529D1 (de)
ES (1) ES2349804T3 (de)
IL (1) IL175692A0 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592150B2 (en) * 2003-12-03 2009-09-22 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
EP1692519B1 (de) * 2003-12-03 2010-06-02 Glycominds Ltd. Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln
DE102004018418A1 (de) * 2004-04-15 2005-11-10 Euroimmun Medizinische Labordiagnostika Ag Diagnose entzündlicher Darmerkrankungen, insbesondere Colitis ulcerosa
WO2006002382A2 (en) * 2004-06-24 2006-01-05 The Scripps Research Institute Arrays with cleavable linkers
US20090220989A1 (en) * 2005-12-05 2009-09-03 Guava Technologies Particle-Based Analyte Characterization
EP2220507B1 (de) * 2007-11-30 2012-09-12 Glycominds Ltd. Zusammensetzung und verfahren zur vorhersage eines komplizierten krankheitsverlaufs und von operationen bei morbus crohn
EP2359137A4 (de) * 2008-11-11 2012-05-30 Prometheus Lab Inc Verfahren zur vorhersage einer entzündlichen darmerkrankung (ibd) anhand serologischer marker
CN101403749B (zh) * 2008-11-17 2012-11-07 北京大学 通过葡聚糖特异性抗体辅助诊断自身免疫性疾病的试剂盒
CN104007102A (zh) * 2013-02-21 2014-08-27 林斯 板式化学发光免疫诊断试剂通用固相包被板及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292667A (en) 1988-06-29 1994-03-08 The General Hospital Corporation Detection and treatment of ulcerative colitis
AU2484892A (en) * 1991-08-09 1993-03-02 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
US5932429A (en) 1996-04-12 1999-08-03 Cedars-Sinai Medical Center Methods of diagnosing clinical subtypes of crohn's disease
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US6084092A (en) * 1997-01-31 2000-07-04 The Collaborative Group, Ltd. β(1-3)-glucan diagnostic assays
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6994966B2 (en) 2000-02-17 2006-02-07 Glycominds Ltd. Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
HUP0200814A3 (en) 1999-02-17 2003-01-28 Glycominds Ltd Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
FR2802536B1 (fr) * 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
AU1861001A (en) 1999-11-29 2001-06-12 Syntesome Gesellschaft Fur Medizinische Biochemie Mbh Arrays of glycan molecules (glycoarrays) on the surface of biochips (glycochips)and uses thereof
US6872540B2 (en) 2001-10-26 2005-03-29 Techlab, Inc. Method and apparatus for distinguishing Crohn's disease from ulcerative colitis and other gastrointestinal diseases by detecting the presence of fecal antibodies to Saccharomyces cerevisiae
DE60317070T2 (de) 2002-08-02 2008-07-24 Glycominds Ltd. Verfahren zur diagnose von multipler sklerose
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US20060205022A1 (en) * 2003-12-03 2006-09-14 Nir Dotan Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease
EP1692519B1 (de) * 2003-12-03 2010-06-02 Glycominds Ltd. Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln
US7592150B2 (en) * 2003-12-03 2009-09-22 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies

Also Published As

Publication number Publication date
ES2349804T3 (es) 2011-01-11
US20100099124A1 (en) 2010-04-22
US7592150B2 (en) 2009-09-22
IL175692A0 (en) 2008-02-09
ATE470152T1 (de) 2010-06-15
US20050142618A1 (en) 2005-06-30
US20050124006A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
Arif et al. Blueprint of quartz crystal microbalance biosensor for early detection of breast cancer through salivary autoantibodies against ATP6AP1
WO2005054853A3 (en) Method for diagnosing diseases based on levels of anti-glycan antibodies
Sporea et al. How many measurements are needed for liver stiffness assessment by 2D-Shear Wave Elastography (2D-SWE) and which value should be used: the mean or median?
NO339224B1 (no) Bedrede immunprøvemetoder
BRPI0311233A2 (pt) diagnóstico de carcinoma hepatocelular
SE0400191D0 (sv) A test kit for detecting periodontal disease
IL175692A0 (en) Method for diagnosing diseases based on levels of anti-glycan antibodies
ATE411769T1 (de) Nichtinvasives messgerät für den lebenden körper
DE602004030586D1 (de) Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
IL193426A0 (en) Methods for the diagnosis of dementia and other neurological disorders
Wong et al. Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe
CY1107859T1 (el) Μεθοδος για διαγνωση πολλαπλης σκληρυνσης
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
DE60228557D1 (de) Candida-nachweis
CN106232809A (zh) Mmp‑8活化产物及其测定和用途
KR20200086678A (ko) 뉴클레오시드 리버스 트랜스크립타제 억제제 요법에 대한 준수를 모니터링하기 위한 생성물 및 방법
ATE420364T1 (de) Verfahren zur magenkrebsvorhersage
ATE466285T1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
WO2014083226A1 (es) Anticuerpos para la detección y cuantificación de agentes anticoagulantes
ATE511646T1 (de) Diagnose mykobakterieller infektionen mittels bestimmung von ifn-gamma
Kotlyar et al. Noninvasive monitoring of hepatitis C fibrosis progression
DK2095126T3 (da) Fremgangsmåde til påvisning af humant parvovirusantigen
DE602004013355D1 (de) Verwendung des proteins spee als marker für brustkrebs
ES2669426T3 (es) Haptenos y conjugados derivados de piocianina, anticuerpos de los mismos, y método inmunoquímico para la detección de infecciones provocadas por pseudomonas aeruginosa